Kitazawa 1990.

Methods	Study design: parallel‐group RCT Country: not reported Number randomized: Total: 23 eyes (17 participants) Per group: not reported Exclusions after randomization: not reported Number analyzed: Total: not reported Per group: not reported Unit of analysis: eyes Losses to follow‐up: not reported How was missing data handled?: not reported Reported power calculation: no Unusual study design?: none
Participants	Age: not reported Females: not reported Inclusion criteria: participants with POAG undergoing ALT Exclusion criteria: not reported Equivalence of baseline characteristics: not reported
Interventions	Intervention 1: 1 drop apraclonidine 1%, 1 hour before and immediately after ALT Intervention 2: 1 drop placebo, 1 hour before and immediately after ALT Length of follow‐up: Planned: 24 hours Actual: 24 hours
Outcomes	Primary outcomes: IOP, flare intensity Secondary outcomes: not reported Adverse events reported: no Intervals at which outcomes assessed: participants observed during a 24‐hour observation period, but specific time points not described.
Notes	Trial registration: not reported Funding sources: not reported Disclosures of interest: not reported Study period: not reported Reported subgroup analyses: no
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Low risk	"We studied the effects of this compound on the inflammatory reaction and the IOP responses to ALT in a randomized, double‐masked manner."
Masking of outcome assessment (detection bias)	Low risk	"We studied the effects of this compound on the inflammatory reaction and the IOP responses to ALT in a randomized, double‐masked manner."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether there were any missing data or how they were handled.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective outcome reporting.
Other bias	Unclear risk	Funding sources not reported.